Previous in vitro studies have demonstrated that resveratrol is able to significantly inhibit the upregulation of mucin 5AC (MUC5AC), a major component of mucus; thus indicating that resveratrol may have potential in regulating mucus overproduction. However, there have been few studies regarding the resveratrol-mediated prevention of MUC5AC overproduction in vivo, and the mechanisms by which resveratrol regulates MUC5AC expression have yet to be elucidated. In the present study, an ovalbumin (OVA)-challenged murine model of asthma was used to assess the effects of resveratrol treatment on mucus production in vivo. The results demonstrated that resveratrol significantly inhibited OVA-induced airway inflammation and mucus production. In addition, the mRNA and protein expression levels of MUC5AC were increased in the OVA-challenged mice, whereas treatment with resveratrol significantly inhibited this effect. The expression levels of murine calcium-activated chloride channel (mCLCA)3, an important key mediator of MUC5AC production, were also reduced following resveratrol treatment. Furthermore, in vitro studies demonstrated that resveratrol significantly inhibited human (h)CLCA1 and MUC5AC expression in a dose-dependent manner. These results indicated that resveratrol was effective in preventing mucus overproduction and MUC5AC expression in vivo, and its underlying mechanism may be associated with regulation of the mCLCA3/hCLCA1 signaling pathway.
Introduction
Asthma is one of the most common chronic inflammatory diseases worldwide. The prevalence of asthma has increased significantly in recent decades, and it currently affects ~300 million individuals worldwide (1) . It is estimated that the number of people diagnosed with asthma will increase to 400 million by 2025 (2) . Further research regarding asthma is essential, since certain symptoms, including mucus overproduction, are currently incurable.
Mucus production has a key role in bronchial asthma, and contributes to the morbidity and mortality of the disease. There are ~20 mucin genes in humans, which are designated MUC followed by a number (3) . Mucin 5AC (MUC5AC), is a major component of mucus that has been reported to have a key role in the process of mucus overproduction in asthma (4, 5) . Various inflammatory cytokines, including tumor necrosis factor (TNF)-α, bacterial products, growth factors and chemicals are able to activate transcription factors, such as specificity protein 1 (Sp1), cAMP response element-binding protein (CREB), and nuclear factor-κB, which may induce the expression of MUC5AC mRNA and protein in airway epithelial cells (6) . Nakanishi et al (6) demonstrated that the introduction of human calcium-activated chloride channel (hCLCA1) into human NCI-H292 cells induced mucus production and MUC5AC expression. In addition, Kang et al (7) reported that a bidirectional circuit between the Notch and epidermal growth factor receptor signaling pathways was able to regulate MUC5AC expression. The transcriptional mechanism that regulates MUC5AC/Muc5ac expression is well-defined; however, there are currently no satisfactory treatments for mucus overproduction. At present, glucocorticoids are used most frequently to reduce mucus production; however, their effects are not always optimal.
Resveratrol (trans-3,5,4'-trihydroxystilbene) is a polyphenol that is present in numerous types of plants, including grapes. Resveratrol exhibits a wide range of biological and pharmacological activities, such as anticarcinogeneic, cardiovascular protective and anti-inflammatory activities. Previous studies have reported on the anti-asthmatic effects of resveratrol in murine models of asthma. Treatment with resveratrol has been shown to inhibit the levels of T helper (Th)2 cytokines interleukin (IL)-4 and IL-5, airway hyperresponsiveness and Resveratrol inhibits mucus overproduction and MUC5AC expression in a murine model of asthma ZHEN-HUA NI  1* , JI-HONG TANG  2* , GUO CHEN  2 , YI-MIN LAI  2 , QING-GE CHEN  2 ,   ZAO LI  2 , WEI YANG  2 , XU-MIN LUO  2 and XIONG-BIAO WANG eosinophilic infiltration (8, 9) . In addition, in vitro studies have demonstrated that benzo(a)pyrene (10), epidermal growth factor, phorbol 12-myristate 13-acetate and TNF-α-induced MUC5AC upregulation and mucin production were inhibited by resveratrol in NCI-H292 human bronchial epithelium cells (11) . These results indicated the potential application of resveratrol in regulating mucus overproduction. However, there have been few studies regarding resveratrol-mediated prevention of MUC5AC overproduction in vivo, and the mechanisms by which resveratrol regulate MUC5AC expression have yet to be elucidated. Therefore the present study aimed to assess the expression levels of MUC5AC and its upstream genes in a murine model of asthma following treatment with resveratrol. The results demonstrated that resveratrol was effective in preventing mucus overproduction and inhibiting MUC5AC expression in vivo.
Materials and methods

Animals.
Female BALB/c mice (8-12 weeks-old) were purchased from Sino-British SIPPR/BK Lab Animal Ltd. (Shanghai, China). All experimental procedures complied with the International Standards of Animal Welfare, and were approved by the Institute Animal Care and Use Committee of Shanghai University of Traditional Chinese Medicine (Shanghai, China).
Ovalbumin (OVA)-induced murine model of asthma, and resveratrol treatment.
A total of 30 female BALB/c mice were divided into three groups: The normal control group (saline-challenged mice treated with saline; n=10/group), the asthma group (OVA-challenged mice treated with saline; n=10/group), and the resveratrol group (OVA-challenged mice treated with resveratrol; n=10/group). The murine asthma model was established as previously described (12) . Briefly, all mice from the asthma and resveratrol groups were immunized by intraperitoneal (IP) injection with 100 µg OVA (Sigma-Aldrich, St. Louis, MO, USA) complexed with alum on days 0 and 15, whereas the mice in the control group received an injection of saline. The mice in the asthma and resveratrol groups received an intranasal dose of 100 µg OVA on days 15, 26, 27 and 28, whereas the mice in the control group received saline. Between days 29 and 35, the resveratrol group was injected with 30 mg/kg resveratrol (IP; Sigma-Aldrich) once a day according to the method of Lee et al (7) ; the control and asthma groups received saline.
On day 36, the mice from all groups were sacrificed by cervical dislocation. The chest was opened using surgical scissors, and the lungs were removed from the thoracic cavity by careful dissection and were washed with saline. The left lungs were collected for histological analyses, and the right lungs were collected for RNA extraction.
Lung histopathology. The left lungs of the mice were harvested and fixed with 2 ml of 10% neutral-buffered formalin (Sigma-Aldrich). Once fixed in neutral-buffered formalin for 72 h, the lung tissues were embedded in paraffin, and cut into 4-µm serial sections using a microtome (Leica RM2235; Leica Biosystems Nussloch GmbH, Nußloch, Germany). The tissue sections were stained with hematoxylin and eosin (H&E) solution (Beyotime Institute of Biotechnology, Haimen, China), in order to evaluate airway inflammation; and periodic acid schiff (PAS) solution (Shanghai Sunbio Medical Biotechnology Co., Ltd., Shanghai, China), in order to assess mucus production, according to the manufacturer's protocol. Tissue sections were observed and images were captured using an optical microscope (DM300; Leica, Wetzlar, Germany). The degree of airway inflammatory cell infiltration was evaluated according to the Underwood scoring system (13) on a scale of 0-4 (0, none; 1, mild; 2, moderate; 3, marked; and 4, severe). Goblet cell hyperplasia in airway epithelium was evaluated by the following scoring system: 0, <5% goblet cells; 1, 5-25%; 2, 25-50%; 3, 50-75%; and 4, >75%, as outlined by Lee et al (8) . The scores were measured in a double-blind manner by two independent investigators.
Immunohistochemistr y for M UC5AC and murine (m)CLCA3 detection. Immunohistochemistry was conducted as described previously (14) . Tissue sections from the left lungs of the mice were deparaffinized in xylene, and rehydrated in graded ethanol. Sections were boiled at a constant temperature of 95˚C for 15 min in citrate buffer (0.01 mmol/l; pH 6.0; Fuzhou Maixin Biotechnology Development Co., Ltd., Fuzhou, China) for antigen retrieval. The tissue sections were then incubated with biotin-labeled mouse monoclonal anti-mouse MUC5AC (cat. no. ab79082; diluted 1:200) or rabbit polyclonal anti-mouse mCLCA3 (cat. no. ab46512; diluted 1:4000) antibodies (both Abcam, Cambridge, UK) at 4˚C overnight. Subsequently, the tissue sections were washed three times with phosphate-buffered saline (PBS) and incubated for 30 min with horseradish peroxidase (HRP)-Streptavidin (cat. no. 43-8323; diluted 1:1,000; Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) or HRP-conjugated anti-rabbit immunoglobulin (Ig)G secondary antibody (cat. no. k4002; Dako Corp., Glostrup, Denmark). Tissue sections were then washed three times with PBS and stained with diaminobenzidine (Fuzhou Maixin Biotechnology Development Co., Ltd., Fuzhou, China). Images were captured using a Leica DM300 microscope (DM300; Leica). Image-Pro Plus 6.0 software (Media Cybernetics, Inc., Rockville, MD, USA) was used to measure the area and integrated optical density (IOD) of the stained slides, and the staining intensity was determined by mean IOD (mean IOD=IOD/area).
Reverse transcription-quantitative polymerase chain reaction (qPCR).
Total RNA was isolated from the right lung tissues of the mice using TRIzol ® reagent (Invitrogen; Thermo Fisher Scientific, Inc.) as described previously (12) . First-strand cDNA was prepared using random hexamer primers provided with the SuperScriptIII™ First-Strand Synthesis kit (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer's protocol. qPCR was performed using a Universal Master mix (Roche Diagnostics, Indianapolis, IN, USA) on an ABI Real-Time PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.). The primer sequences (Sangon Biotech Co., Ltd., Shanghai, China) are listed in Table I . Each assay was performed in triplicate. The PCR cycling conditions used for all reactions were as follows: 10 min at 95˚C, followed by 40 two-step cycles at 95˚C for 15 sec and 60˚C for 1 min. The relative expression levels of the target genes were normalized against glyceraldehyde 3-phosphate dehydrogenase and analyzed using REST2009 software (14) .
Cell culture. The 16HBE human lung epithelial cell line (Bogoo Biotech Co., Ltd., Shanghai, China) was cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (Invitrogen). Briefly, 1x10 6 cells were seeded into a 100-mm dish and incubated overnight. After 24 h, the 16HBE cells were treated with 10 or 50 µmol/l resveratrol for 72 h. An equivalent volume of vehicle (dimethyl sulfoxide; Sigma-Aldrich) was added to the control cells. Following a 72-h incubation at 37˚C, the cells were harvested for western blotting.
Western blot analysis. Western blotting was conducted as described previously (15) . Total protein was isolated from the cells using ProteoJET™ Mammalian Cell Lysis Reagent (Fermentas; Thermo Fisher Scientific, Inc., Pittsburgh, PA, USA). The protein fractions (40 µg per lane) were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and then transferred to a polyvinylidene fluoride (PVDF) membrane (EMD Millipore, Bedford, MA, USA). The PVDF membrane was blocked with 5% bovine serum albumin (Sigma-Aldrich) and washed twice with Tris-buffered saline containing Tween (TBST; Beyotime Institute of Biotechnology). The membrane was then incubated with biotin-labeled mouse monoclonal anti-human MUC5AC (cat. no. ab79082; diluted 1:1,000; Abcam), anti-hCLCA1 (cat. no. 7072; diluted 1:1,000; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) and rabbit monoclonal anti-human GAPDH (cat. no. 5174S; diluted 1:1,000; Cell Signaling Technology, Inc., Danvers, MA, USA) antibodies overnight at 4˚C, and washed three times with TBST. Subsequently, the membrane was incubated with HRP-Streptavidin (Invitrogen) or HRP-conjugated anti-mouse IgG secondary antibody (Cell Signaling Technology, Inc.) for 2 h at room temperature. Finally, immunoreactive bands were detected using enhanced chemiluminescence (EMD Millipore, Bedford, MA, USA).
Statistical analysis. SPSS version 16.0 software (SPSS, Inc., Chicago, IL, USA) was used for data analyses. Data are presented as the mean ± standard deviation. Statistical significance was determined by Student's t-test or Mann-Whitney U test. P<0.05 was considered to indicate a statistically significant difference.
Results
Effects of resveratrol on airway inflammation and mucus production in the lung tissue of a murine model of asthma.
Histological analysis of the lung sections detected differences in inflammation between the various groups. Treatment with resveratrol reduced airway inflammation in the lung tissues, as compared with the asthma group ( Fig. 1A-C ; P= 0.002), thus suggesting that resveratrol exerted anti-inflammatory effects. In addition, PAS staining was used to evaluate mucus production. Mucus production in the asthma group was increased, as compared with the control group, whereas mucus production was decreased in the resveratrol-treated group, as compared with the asthma group ( Fig. 2A-C ; P= 0.001). These results were consistent with previous observations (8) . These data Effects of resveratrol on MUC5AC expression. MUC5AC is the major component of mucus in asthma among the products of 20 mucin genes (5), and the expression levels of MUC5AC may represent the intensity of mucin expression. To determine whether resveratrol-induced inhibition of mucus production was associated with reduced MUC5AC expression, MUC5AC protein expression was determined using immunohistochemistry. As shown in Fig. 3 , MUC5AC expression was increased in the asthma group, as compared with the control group (P<0.001). Conversely, treatment with resveratrol significantly inhibited MUC5AC protein expression (P= 0.022, vs. the asthma group). In addition, reduced mRNA expression levels of MUC5AC were detected in the resveratrol-treated mice, as compared with those in the OVA-challenged mice (Table II; P<0.001). These data suggest Table II . Relative expression of mucin 5AC (MUC5AC) and MUC5AC-associated genes, compared with the asthma group. that resveratrol may inhibit mucus production by regulating MUC5AC transcription.
Asthma group Normal group
Resveratrol group ------------------------------- ------------------------------------------------------------------ ---------------------------------------------------------------- Gene
Ef fects of resveratrol on the expression of nine MUC5AC-related genes.
To explore the possible signal pathway underlying resveratrol-induced MUC5AC inhibition, nine MUC5AC-related genes were selected from the MUC5AC core gene list compiled by Wang et al (16) . These genes were the key mediators of Wnt, Notch, mitogen-activated protein kinases and signal transducer and activator of transcription (STAT)6 pathways, and had been reported to affect the expression of MUC5AC. In the present study, two genes [mCLCA3and cathepsin C (CTSC)] were overexpressed in the asthma group, as compared with the control group (Table II; P<0.001 for mCLCA3; P= 0.046 for CTSC). However, only mCLCA3 mRNA expression was reduced following resveratrol treatment (Table II; P<0.001). Consistent with these results, immunohistochemistry revealed that mCLCA3 protein expression was reduced in the resveratrol group, as compared with the asthma group ( Fig. 4 ; P=0.001).
Effects of resveratrol on hCLCA1 and MUC5AC expression in a lung epithelial cell line. To examine whether resveratrol could effectively inhibit hCLCA1 and MUC5AC expression in human cells, the 16HBE human lung epithelial cell was treated with 10 or 50 µmol/l resveratrol for 72 h. Resveratrol markedly inhibited hCLCA1 and MUC5AC protein expression in a dose-dependent manner (Fig. 5) . These results confirmed the effects of resveratrol on regulating CLCA expression.
Discussion
Mucus hypersecretion is a common symptom of asthma, and is an important factor in asthma-associated mortality. The present study demonstrated that resveratrol was an effective reagent in a murine model of asthma, particularly by suppressing mucus production. In addition, it was suggested that the effects of resveratrol on mucus production may be associated with the downregulation of MUC5AC overexpression, via the mCLCA3/hCLCA1 signaling pathway.
The CLCA family consists of numerous members. The hCLCA subfamily has four members: hCLCA1, hCLCA2, 
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hCLCA3 and hCLCA4, whereas the Mus musculus subfamily has at least five members. hCLCA1, an ortholog of the murine CLCA3, has an important role in mucus hypersecretion (17) . Overexpression of hCLCA1 in human NCI-H292 cells has previously been demonstrated to induce mucus production and MUC5AC expression (6) . Consistent with these results, mCLCA3 antibodies may significantly reduce MUC5AC expression (18) . In addition, the protein and mRNA expression levels of mCLCA3 and MUC5AC were significantly increased in lung tissue when mCLCA3 plasmids were transfected into the airways of normal BALB/c mice (19) . In the airway hyperresponsiveness mouse model, inhibiting mCLCA3 expression by intra-tracheal administration of an adenovirus expressing mCLCA3 antisense RNA efficiently suppressed the asthma phenotype and mucus overproduction (6) . Therefore, targeting hCLCA1/mCLCA3 may be an effective method for the modulation of mucus production. CLCA protein is secreted from cells, bound to the CLCA receptor, which stimulates an increase in MUC5AC and MUC5B expression, which in turn leads to enhanced mucin secretion (20) . Therefore, it may be hypothesized that decreasing mCLCA3 expression is at least one of the mechanisms by which resveratrol inhibits MUC5AC expression. However, the mechanism by which resveratrol modulates mCLCA3 expression remains unclear. The authors of the present study hypothesize that regulation of mCLCA3 may be either direct or indirect. It has previously been reported that mCLCA3 was upregulated by Th2 cytokines (IL-4, IL-9 and IL-13) in a murine model of asthma, possibly via Janus kinase (JAK)/STAT6 signaling (21, 22) . Previous studies have demonstrated that resveratrol reduced the levels of IL-4 and IL-13 in asthmatic mice (8, 23 ); therefore, it is possible that resveratrol may decrease mCLCA3 expression by inhibiting the expression of Th2 cytokines. Concurrently, resveratrol may prevent phosphorylation of JAK or inhibit the expression of JAK-1 directly, and thereby inhibit STAT6 phosphorylation (24) . The mouse CLCA and human CLCA gene promoter regions contain consensus STAT6-binding sites. It has previously been demonstrated that hCLCA1 may be regulated by the JAK/STAT6 signaling pathway in humans (20) . Furthermore, resveratrol has been shown to inhibit extracellular signal-regulated kinases (ERK)1/2 activation (25), and it has been suggested that hCLCA1 may be regulated by ERK signaling pathways (20) . Therefore, there may be numerous signaling pathways underlying the resveratrol-mediated regulation of CLCA expression.
In conclusion, the results of the present study demonstrated that resveratrol may effectively suppress mucus overproduction in a murine model of asthma. The decreased mucus production was mediated partially by the regulation of mCLCA3/hCLCA1 gene expression, which consequently downregulated MUC5AC expression. Further research is required to determine the signaling pathway underlying resveratrol-mediated mCLCA3 regulation.
